Clinical trials: Vasodilatory Shock
Vasodilatory Shock
Synthetic Angiotensin II/Giapreza in Pediatric Patients With Refractory Hypotension
The goal of this clinical trial is to determine the safety and efficacy of Angiotensin-II in the treatment of pediatric patients in fluid refractory vasodilatory shock.
- Trial name
- NCT07212686
- Testing
- Angiotensin-II
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Northwell Health
Septic Shock, Vasodilatory Shock
Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock
This trial will be a randomized controlled single-center pilot trial comparing the use of angiotensin II versus standard-of-care (SOC) vasopressor therapy in adult patients with persistent vasodilatory shock despite moderate-dose…
- Trial name
- DARK-Sepsis (NCT05824767)
- Testing
- Angiotensin II
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of New Mexico
Septic Shock, Cirrhosis
Comparison of Angiotensin II to Standard Dose Vasopressors on Change in Arterial Elastance
A study to see whether a medication called Angiotensin II works better than the routinely used medication to raise blood pressure in people with liver disease who are experiencing a serious drop in blood pressure.
- Conditions
- Septic Shock, Cirrhosis, Vasodilatory Shock, Acute Kidney Injury
- Trial name
- Ang2 (NCT07568275)
- Testing
- Giapreza
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
Septic Shock, Vasodilatory Shock
Vasopressin Use in Septic Shock From Türkiye
The goal of this observational study is to examine the early hemodynamic effects and clinical outcomes of vasopressin use in patients with septic shock.
- Conditions
- Septic Shock, Vasodilatory Shock, Critical Illness Sepsis, Severe, Critical Illness
- Trial name
- (VASCO-TURK) (NCT06953297)
- Where
- Turkey (Türkiye)
- Volunteers
- 146 people
- Sponsor
- Karadeniz Technical University
Vasodilatory Shock
Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock
A randomized, double-blind, placebo-controlled study on the treatment of refractory distributed shock with angiotensin II injection, with a random ratio of 1:1.
- Trial name
- NCT06351150
- Testing
- Angiotensin II Injection, 0.9% sodium chloride injection
- Where
- 42 sites in China
- Volunteers
- 214 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Septic Shock, Vasodilatory Shock
Heparin Anticoagulation in Septic Shock
This study is a pragmatic open-label international randomized trial comparing therapeutic dose intravenous unfractionated heparin (UFH) to standard care venous thromboprophylaxis in patients diagnosed with septic shock.
- Trial name
- HALO (NCT03378466)
- Testing
- Unfractionated heparin, Venous thromboprophylaxis (VTE)
- Where
- 51 sites in United States, Brazil and 5 more
- Volunteers
- 178 people
- Sponsor
- University of Manitoba
Catecholamine Resistant Hypotension (CRH), Distributive Shock
Expanded Access for LJPC-501
The primary objective of the study is to provide access to LJPC-501 for distributive shock patients who remain hypotensive despite receiving fluid and vasopressor therapy.
- Conditions
- Catecholamine Resistant Hypotension (CRH), Distributive Shock, High Output Shock, Sepsis
- Trial name
- NCT03245528
- Testing
- LJPC-501
- Sponsor
- La Jolla Pharmaceutical Company